> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Frazier Co-Founders Topper And Heron Report 7.4% Stake In Phathom After Updating Filing
- URL: https://www.bullished.co/frazier-co-founders-topper-and-heron-report-7-4-stake-in-phathom-after-updating-filing-3a543fe1/
- Published: 2026-11-02T21:46:10.000Z
- Updated: 2026-11-02T21:46:10.000Z
- Description: James Topper's 6,013,327 shares equal 7.4% of Phathom, the latest amendment to the Frazier group's ownership statement shows.
- Author: Matteo Parrino
- Tags: SEC Filings, PHAT, Industry: Healthcare, Topic: Ownership & Activism

James Topper, who shares control of two Frazier Life Sciences funds with Patrick Heron, reports owning [6,013,327 shares](https://www.sec.gov/Archives/edgar/data/0001863769/000123191926001523/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) of [Phathom Pharmaceuticals](https://www.bullished.co/tag/phat/), or 7.4% of the common stock, in an ownership amendment filed Monday. The filing updates addresses and holdings, and the event date is October 29, 2026.

## How the 7.4% adds up

Topper's total includes [80,000 options](https://www.sec.gov/Archives/edgar/data/0001863769/000123191926001523/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) he holds directly and shares held through Frazier Life Sciences IX and X. His percentage is figured on 81,291,520 shares outstanding as of October 27, plus those options.

Heron reports 5,901,756 shares, or 7.3%. Frazier Life Sciences IX alone holds 5,827,415 shares, or 7.2%, and Frazier Life Sciences X holds 59,403\. Heron and Topper are the members of the general partner's management entity for those funds, so they share voting and investment power over those shares.

Frazier Life Sciences Public Fund holds 5,323,356 shares, or 6.5%. Its general partner is run by an investment committee of four, so no committee member is attributed ownership of those shares. Frazier Life Sciences XI holds 980,286 shares, or 1.2%, and XII holds 276,029, or 0.3%; each is governed by a three-person committee on the same basis.

## Warrants outside the count

The tallies exclude warrants whose exercise is capped by ownership limits. The Public Fund holds warrants for 2,596,399 shares under a 9.99% cap, and XI holds 12,523 under the same cap.

A second set carries a 19.99% cap: 1,109,569 shares for the Public Fund, 10,376 for XI and 130,133 for XII.

## A housekeeping amendment

Amendment No. 12 changes only two items: the reporting persons' business address, now in Palo Alto, California, and the ownership section. The funds are all Delaware entities, and Topper and Heron are U.S. citizens.

Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company selling gastrointestinal treatments. Its VOQUEZNA tablets and two VOQUEZNA pak products contain vonoprazan, an acid blocker approved for reflux disease and Helicobacter pylori infection. Its market value was $467 million in Monday trading.

The filing's share percentages rest on the 81,291,520 shares Phathom reported in its quarterly report filed October 29.

Learn

- [13D Filing Requirements And Deadline, Shown With Real Filings →](https://www.bullished.co/learn/13d-filing-requirements/)  
A Schedule 13D is required when you own more than 5% of a public company's voting shares. See the deadline, contents and real filings from this week.
- [13D Vs 13G: What Each 5% Stake Filing Means And How To Read One →](https://www.bullished.co/learn/13d-vs-13g/)  
13D vs 13G: both report stakes above 5%, but 13G is the short passive form and 13D explains intent. See real BlackRock and Pictet filings read in plain English.

### Sources

- [SCHEDULE 13D/A — James N. Topper re: PHATHOM PHARMACEUTICALS, INC. (PHAT)](https://www.sec.gov/Archives/edgar/data/0001863769/000123191926001523/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR

### More on Phathom Pharmaceuticals

- [Phathom Moves To Defend Voquesna's Exclusivity Through May 2032 After Generic Maker Sues FDA](https://www.bullished.co/phathom-moves-to-defend-voquesnas-exclusivity-through-may-2032-after-generic-maker-sues-69fa808e/)
- [Phathom CEO Sees 'Inertia,' Not Resistance, As It Offers $0 Copays On Voquezna](https://www.bullished.co/phathom-ceo-sees-inertia-not-resistance-as-it-offers-0-copays-on-voquezna-d714d4ca/)
- [Phathom Must Now Hold $119.3 Million In Cash For Its Royalty Lenders As A Lawsuit Targets VOQUEZNA Exclusivity](https://www.bullished.co/phathom-must-now-hold-119-3-million-in-cash-for-its-royalty-lenders-as-a-lawsuit-targets-e760135c/)

[All Phathom Pharmaceuticals (PHAT) coverage →](https://www.bullished.co/tag/phat/)